ClinicalTrials.gg
Enrolling by invitationNCT07580404Updated Oct 15, 2026

Emsella for Reducing tSUI After HOLEP

An interventional study of Emsella chair in Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms and Enlarged Prostate (BPH), sponsored by Northwestern University. Enrolling by invitation at 1 site in United States. Open to male participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Northwestern University · Not applicable, Interventional, and Other

How we know

Updated Oct 15, 2026Now Enrolling by invitationStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Prostatic Hyperplasia by Northwestern University — 4 open to participants now, 5 under way, none of them phase 3. Prostatic Hyperplasia · Northwestern University.

Started
2026
with 2 others
No phase
7 of 10
3 open now
Registered
7th of 10
by date

Among the 10 studies in Prostatic Hyperplasia by Northwestern University, this one is one of 3 that started in 2026, is one of 7 with no phase, and was the 7th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

4 of the 10 studies in Prostatic Hyperplasia by Northwestern University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years to 80 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Prostatic Hyperplasia by Northwestern University, or all of them as a file.
02

Study summary

This study aims to investigate the effectiveness of the Emsella chair treatments at different timepoints. Before and after the holmium laser enucleation of the prostate (HoLEP).

Read the detailed description

Emsella is a non-invasive treatment used to activate and strengthen the pelvic floor. One Emsella treatment is reported to be the equivalent of performing 11,000 Kegel exercises. This study aims to examine the effectiveness of Emsella chair treatments in reducing the likelihood of tSUI following HoLEP by comparing the outcomes of patients who completed treatments at different points of time around their HoLEP procedure.

03

Conditions studied

  • Benign Prostatic Hyperplasia
  • Enlarged Prostate With Lower Urinary Tract Symptoms
  • Enlarged Prostate (BPH)

Browse trials for

Keywords

  • HoLEP
  • Emsella
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prostate sizing 80-150g
  • Ability to independently transfer and tolerate all 30min Emsella treatments (e.g. not wheelchair bound, no mobility issues)
  • Baseline M-ISI scores \<4
  • Same-day catheter removal and discharge
  • Able to read, understand, and complete surveys and questionnaires

Exclusion criteria

Exclusion Criteria:

  • Catheter dependence
  • Previous BPH procedure
  • Previous pelvic surgeries
  • Pre-existing pelvic floor dysfunction
  • Neurogenic bladder
  • Overactive bladder - e.g. prescribed and taking any oxybutynin or mirabegron
  • Preoperative pad-use for incontinence
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • No intervention
    Standard Care (Kegel Exercises)

    Patients are reminded to perform pelvic floor exercises known as Kegel exercises for 3 weeks leading up to their scheduled HoLEP procedure, and continue Kegel exercises for 3 weeks following the HoLEP procedure.

  • Active comparator
    Pre-HoLEP Emsella

    Participants will complete 2 30-minute Emsella treatment sessions for 3 weeks (for a total of 6 30-minute Emsella chair treatment sessions) leading up to their scheduled HoLEP procedure. They will undergo the HoLEP 1 week after the final Emsella treatment session.

    Device: Emsella chair

  • Active comparator
    Post-HoLEP Emsella

    Participants will complete 2 30-minute Emsella treatment sessions for 3 weeks (for a total of 6 30-minute Emsella chair treatment sessions) following their scheduled HoLEP procedure. They will begin their first Emsella treatment session 1 week after HoLEP.

    Device: Emsella chair

Interventions

  • DeviceEmsella chair

    Emsella is a non-invasive treatment used to activate and strengthen the pelvic floor. One Emsella treatment is reported to be the equivalent of performing 11,000 Kegel exercises.

06

What researchers measure

Primary outcomes

  1. Difference in Michigan Incontinence Score (M-ISI)

    The Michigan Incontinence Score (M-ISI) is a 10-item questionnaire designed to assess urinary incontinence type, severity, and bother, with a focus on stress and urge incontinence. The tool is commonly used to screen for clinically relevant symptoms, with a total score of greater than or equal to 7 suggesting a need for intervention.

    Time frame: Pre-HoLEP, 4 weeks, 6 weeks, 8 weeks, 12 weeks post-HoLEP

  2. Difference in International Prostate Symptom Score (IPSS)

    The International Prostate Symptom Score (IPSS) is a 7-question tool (0-35 points) used in urology to assess Benign Prostatic Hyperplasia (BPH) severity, plus one quality-of-life question. It measures symptoms like frequency, urgency, weak stream, and nocturia, with scores of 0-7 (Mild), 8-19 (Moderate), and 20-35 (Severe).

    Time frame: Pre-HoLEP, 4 weeks, 6 weeks, 8 weeks, 12 weeks post-HoLEP

Secondary outcomes

  1. Difference in safety/adverse effects

    Adverse effects reported by patient or detected from hospital and ER admissions within 3 months after procedure.

    Time frame: 12 weeks post-HoLEP

Other outcomes

  1. Difference in patient reported symptoms

    Patient reported symptoms via REDCap surveys related to gross hematuria, dysuria, incontinence after HoLEP.

    Time frame: 6 months post-HoLEP

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

Of 155 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's planned 12 months is below that.

Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Jun 2026 → Jul 2026, primary completion Jun 2027 → Jul 2027 and completion Jun 2028 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2026
First posted
May 12, 2026
StartActual
Jul 24, 2026was Jun 2026
Primary completionEst.
Jul 2027was Jun 2027
CompletionEst.
Jul 2028was Jun 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 15, 2026
Start date
Jun 2026→Jul 24, 2026 (actual)
Oct 15, 2026
Primary completion
Jun 2027→Jul 2027
Oct 15, 2026
Study completion
Jun 2028→Jul 2028
Oct 15, 2026
Contact
No study contact listed any more: removed a•••@northwestern.edu · •••8146
Oct 15, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Northwestern University · Chicago, United StatesContact removed (no phone or email listed)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Jun 2026→Jul 24, 2026 (now actual)
    Primary completion Jun 2027→Jul 2027
    Study completion Jun 2028→Jul 2028
    Contact No study contact listed any more: removed a•••@northwestern.edu · •••8146
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Northwestern University · Chicago, United StatesContact removed (no phone or email listed)
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07580404
Responsible party
Amy Krambeck (Director of the Endourology/Stone Division, Northwestern University) — Principal investigator
First posted
May 12, 2026
Start date
Jul 24, 2026
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Amy E Krambeck, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion